Ceftizoxime

{{Short description|Chemical compound}}

{{refimprove|date=April 2013}}

{{Drugbox

| IUPAC_name = (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

| image = ceftizoxime.png

| tradename = Cefizox

| Drugs.com = {{drugs.com|CDI|ceftizoxime}}

| MedlinePlus = a684043

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 68401-81-0

| CAS_supplemental = {{CAS|68401-82-1}}

| ATC_prefix = J01

| ATC_suffix = DD07

| PubChem = 6533629

| DrugBank =

| ChemSpiderID = 5018818

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = C43C467DPE

| KEGG = D07658

| ChEMBL = 528

| C=13 | H=13 | N=5 | O=5 | S=2

}}

Ceftizoxime is a third-generation cephalosporin available for parenteral administration.{{cite journal | vauthors = Aldridge KE | title = An update on the in vitro activity of ceftizoxime and other cephalosporin/cephamycin antimicrobial agents against clinically significant anaerobic bacteria | journal = Clinical Therapeutics | volume = 12 Suppl C | issue = | pages = 3–12 | date = 1990 | pmid = 2202509 | doi = | url = }}

Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes.

It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.